(Q38200143)

30 August 2017

title

The role of P-glycoprotein in drug resistance in multiple myeloma (English)

1 reference

30 August 2017

main subject

multiple drug resistance

1 reference

Joseph Abraham

1

1 reference

30 August 2017

Noha N Salama

series ordinal

2

1 reference

30 August 2017

Abdel Kareem Azab

series ordinal

3

1 reference

30 August 2017

publication date

5 June 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

56

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

26-33

1 reference

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Lenalidomide after stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Can we change the disease biology of multiple myeloma?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Will MDR-1/P-gp modulators provide clinical benefit in hematologic malignancies?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Psorospermin structural requirements for P-glycoprotein resistance reversal

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Major contribution of the multidrug transporter P-glycoprotein to reduced susceptibility of poly(ADP-ribose) polymerase-1 knock-out cells to doxorubicin action

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Multidrug resistance: Clinical relevance in haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Reversal of multidrug resistance in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Genetic variations in multiple myeloma II: association with effect of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Immunosuppressors and reversion of multidrug-resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Biochemical, cellular, and pharmacological aspects of the multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Multidrug resistance in cancer: role of ATP-dependent transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Regulation of ceramide production and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Increased ABCB1 Expression in TP-110-Resistant RPMI-8226 Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Novel generation of agents with proven clinical activity in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Influx and efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Doxorubicin induces drug efflux pumps in Candida albicans.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Insights into oxazaphosphorine resistance and possible approaches to its circumvention.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Comparative effects of drugs on P-glycoprotein expression and activity using rat and human trophoblast models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.907890

10.3109/10428194.2014.907890

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference